| The human symbiont Mucispirillum schaedleri: causality in health and disease S Herp, AC Durai Raj, M Salvado Silva, S Woelfel, B Stecher Medical microbiology and immunology 210 (4), 173-179, 2021 | 119 | 2021 |
| Quasi-essentiality of RNase Y in Bacillus subtilis is caused by its critical role in the control of mRNA homeostasis M Benda, S Woelfel, P Faßhauer, K Gunka, S Klumpp, A Poehlein, ... Nucleic Acids Research 49 (12), 7088-7102, 2021 | 17 | 2021 |
| Intestinal colonization resistance in the context of environmental, host, and microbial determinants S Woelfel, MS Silva, B Stecher Cell host & microbe 32 (6), 820-836, 2024 | 13 | 2024 |
| Systemic and T cell‐associated responses to SARS‐CoV‐2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of … S Woelfel, J Dütschler, M König, N Graf, V Oikonomou, C Krieger, ... Alimentary pharmacology & therapeutics 57 (1), 103-116, 2023 | 13 | 2023 |
| Pulsed antibiotic treatments of gnotobiotic mice manifest in complex bacterial community dynamics and resistance effects PC Münch, C Eberl, S Woelfel, D Ring, A Fritz, S Herp, I Lade, R Geffers, ... Cell Host & Microbe 31 (6), 1007-1020. e4, 2023 | 9 | 2023 |
| STAR SIGN study: Evaluation of COVID‐19 vaccine efficacy against the SARS‐CoV‐2 variants BQ. 1.1 and XBB. 1.5 in patients with inflammatory bowel disease S Woelfel, J Dütschler, M König, A Dulovic, N Graf, D Junker, ... Alimentary pharmacology & therapeutics 58 (7), 678-691, 2023 | 6 | 2023 |
| XBB. 1.5‐Adapted COVID‐19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS‐CoV‐2 JN. 1 Variant in Patients With … S Woelfel, J Dütschler, D Junker, M König, N Graf, C Krieger, S Truniger, ... Alimentary Pharmacology & Therapeutics 61 (2), 299-312, 2025 | 5 | 2025 |
| Systemic and mucosal immunogenicity of monovalent XBB. 1.5-adapted COVID-19 mRNA vaccines in patients with inflammatory bowel disease S Woelfel, J Dütschler, D Junker, M König, G Leinenkugel, N Graf, ... Vaccines 12 (7), 774, 2024 | 4 | 2024 |
| Complete genome sequence of Helicobacter pylori B128 7.13 and a single‐step method for the generation of unmarked mutations EM Dawson, KA Dunne, EJ Richardson, J Praszkier, D Alfawaz, S Woelfel, ... Helicobacter 24 (4), e12587, 2019 | 3 | 2019 |
| Individualising JAK Inhibitor Selection for Patients With Ulcerative Colitis S Woelfel, S Brand Alimentary Pharmacology & Therapeutics, 2025 | | 2025 |
| Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD. Authors' Reply S Woelfel, S Brand Alimentary Pharmacology & Therapeutics 61 (2), 382-383, 2025 | | 2025 |
| STAR LIGHT Study: XBB. 1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN. 1 Variant in Patients with Chronic Liver Disease S Woelfel, D Junker, I Bergamin, P Meyer-Herbon, R Stillhard, N Graf, ... Vaccines 12 (11), 1241, 2024 | | 2024 |
| Systemic and mucosal immune responses against the SARS-CoV-2 XBB. 1.5, EG. 5.1, and BA. 2.86 lineages induced by monovalent XBB. 1.5-adapted COVID-19 mRNA vaccines in patients … S Woelfel, J Dueschlerl, D Junker, M Konig, G Leinenkugel, N Graf, ... SWISS MEDICAL WEEKLY 154, 11S-11S, 2024 | | 2024 |
| Pulsed Antibiotic Treatments of Gnotobiotic Mice Manifests in Complex Community Dynamics and Resistance Effects PC Münch, C Eberl, D Ring, S Woelfel, A Fritz, S Herp, I Lade, R Geffers, ... Available at SSRN 4149957, 0 | | |
